Pro Dex Inc 's ROA from the first quarter of 2026 to the first quarter of 2026 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Pro Dex Inc 's ROA in the first quarter of 2026?
Pro dex Inc achieved a return on average assets (ROA) of 16.65 % in its first quarter of 2026, this is above PDEX's average return on assets of 11.27%.
Pro Dex Inc assets over the 12 months ending in its first quarter of 2026 are valued at $72 million

ROA fell compared to the fourth quarter of 2026, despite the net income growth of 6.69% from the fourth quarter of 2026.

However, within the Healthcare sector 58 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2026 quarter, so far to 258, from total ROA ranking in the fourth quarter of 2026 at 302.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2026) I. Quarter	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter
Y / Y Total Assets Change	20.75 %	21.76 %	15.74 %	-1.29 %	16.74 %
Y / Y Net Income Change	-34.87 %	138.68 %	20.24 %	7.21 %	89.78 %
Net Income (TTM) in million	12	14	12	11	11
Return On Assets (TTM)	16.65 %	19.83 %	18.3 %	17.99 %	17.7 %
PDEX's Total Ranking	# 258	# 302	# 268	# 321	# 302
Total Assets (TTM) in million	78	75	75	62	64
Seq. Total Assets Change	4.44 %	-0.02 %	19.96 %	-3.61 %	5.32 %
Seq. Net Income Change	6.69 %	-27.45 %	80.06 %	-53.27 %	290.98 %

PDEX's 5 Years Annual ROA >> Back to PDEX Management Effectiveness >> Compare PDEX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 12
Sector	# 59
Overall	# 294

Return On Assets Statistics
High	Average	Low
37.1 %	11.27 %	-15.11 %
(Jun 30 2017)		(Jun 30 2013)

Financial Statements
Pro Dex Inc 's Assets	$ 78 million	PDEX's Balance sheet
Pro Dex Inc 's Income	$ 3 million	Quarterly PDEX's Income Statement
PDEX's Income by Division		See PDEX's Income by Division

Annual Return On Assets	(Jun 30 2026) FY 2026	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022
Y / Y Total Assets Change	33.07 %	15.19 %	1.12 %	11.27 %	17.38 %
Total Assets in million	82	61	53	53	47
Y / Y Net Income Change	52.17 %	322.1 %	-69.93 %	83.5 %	-13.37 %
Net Income in million	14	9	2	7	4
Annual Return On Assets	16.74 %	14.64 %	3.99 %	13.43 %	8.15 %

PDEX's 5 Years Annual ROA >> Back to PDEX Management Effectiveness >> Compare PDEX ROA to its Competitors

Comment on PDEX's ROA in the fiscal year ending 2026

In the fiscal year 2026 ROA improved to 16.74 % compared to prior year, due to annual net income growth of 52.17 % to $13.66 million, while value of Pro Dex Inc 's overall assets grew just by 33.07 % to $81.63 million, compared to $81.63 a year before.

More Return On Assets Ratios
PDEX's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PDEX's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PDEX's Competitors
Subscribers only: Roa for Pro Dex Inc 's Suppliers
Subscribers only: Return On Assets for PDEX's Customers

You may also want to know
PDEX's Roi	PDEX's Inventory Turnover Ratio	PDEX's Growth Rates	PDEX's Dividend Comparisons
	PDEX's Profitability Ratios	PDEX's Asset Turnover Ratio	PDEX's Dividend Growth
PDEX's Roe	PDEX's Valuation Ratios	PDEX's Financial Strength Ratios	PDEX's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector	ROA
Ironwood Pharmaceuticals inc	42.53 %
Aurinia Pharmaceuticals Inc	40.63 %
Nurix Therapeutics Inc	38.61 %
Indivior Pharmaceuticals Inc	36.35 %
Rallybio Corporation	34.55 %
Idexx Laboratories Inc	34.05 %
Zevra Therapeutics Inc	26.33 %
Caredx Inc	25.74 %
Medpace Holdings Inc	24.47 %
Acadia Pharmaceuticals Inc	21.60 %
Standard Biotools Inc	21.56 %
Eli Lilly And Company	21.24 %
Iradimed Corporation	20.89 %
Resmed Inc	18.67 %
Alector Inc	18.37 %
Corcept Therapeutics Inc	18.09 %
Chemed Corporation	17.73 %
Halozyme Therapeutics Inc	17.26 %
Pro dex Inc	16.75 %
Denali Therapeutics Inc	16.42 %
Krystal Biotech Inc	15.48 %
West Pharmaceutical Services Inc	15.47 %
Dexcom Inc	15.47 %
Intuitive Surgical Inc	14.71 %
Vertex Pharmaceuticals Inc	14.16 %
Neurocrine Biosciences Inc	13.69 %
Illumina Inc	13.43 %
Healthcare Services Group Inc	12.79 %
Kiniksa Pharmaceuticals International Plc	12.64 %
Tenet Healthcare Corp	12.39 %

Date modified: 2026-10-30T13:19:57+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.